Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Antje Neeb(Institute of Cancer Research), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Joan Carles(Vall d'Hebron Hospital Universitari), George Seed(Institute of Cancer Research), Pasquale Rescigno(Institute of Cancer Research), Wei Yuan(Shanghai Public Health Clinical Center), Veronica Gil(Cancer Research UK), Bora Gürel(Institute of Cancer Research), Jesús Gil(MRC London Institute of Medical Sciences), Caterina Aversa(Royal Marsden NHS Foundation Trust), Joaquı́n Mateo(Royal Marsden NHS Foundation Trust), Verena Wagner(MRC London Institute of Medical Sciences), Jan Rekowski(Institute of Cancer Research), Amanda Swain(Institute of Cancer Research), Susana Miranda(Royal Marsden NHS Foundation Trust), Irene Casanova‐Salas(Vall d'Hebron Institut de Recerca), Ruth Riisnaes(Institute of Cancer Research), Alejandro Athie(Vall d'Hebron Institute of Oncology), Rafael Morales‐Barrera(Universitat Autònoma de Barcelona), Adam Sharp(Institute of Cancer Research), Violeta Serra(Vall d'Hebron Institute of Oncology), Ana Ferreira(Institute of Cancer Research), Nicolás Herranz(Vall d'Hebron Institut de Recerca), Lorenzo Buroni(Institute of Cancer Research), Daniel Nava Rodrigues(Institute of Cancer Research), Jian Ning(Cancer Research UK), Cristina Suárez(Complejo Hospitalario de Salamanca), Sara Arce‐Gallego(Hebron University), Jon Welti(Institute of Cancer Research), Suzanne Carreira(Institute of Cancer Research), Teresa Casals(Duran i Reynals Hospital), Christopher J. Lord(Institute of Cancer Research), Diletta Bianchini(Royal Marsden NHS Foundation Trust), Maria D. Fenor de la Maza(Royal Marsden NHS Foundation Trust), Alec Paschalis(Royal Marsden NHS Foundation Trust), Ines Figueiredo(Institute of Cancer Research), Macarena González(Vall d'Hebron Hospital Universitari), Khobe Chandran(Royal Marsden NHS Foundation Trust), Cláudia Bertan(Institute of Cancer Research), Juliet Carmichael(Royal Marsden NHS Foundation Trust), Sarai Córdoba(Vall d'Hebron Institute of Oncology)
Cited by 118
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k